216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects

BACKGROUND: Xeruborbactam (XERU) is a member of a new class of cyclic boronic acid β-lactamase inhibitors with inhibitory activity against major members of Class A, B, C, and D beta-lactamases. This report describes the safety and pharmacokinetics of XERU following multiple doses alone and in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffith, David, Roberts, Jason, Wallis, Steven, Hernandez-Mitre, Maria Patricia, Morgan, Elizabeth, Gehrke, Shawnee, Dudley, Michael, Loutit, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752152/
http://dx.doi.org/10.1093/ofid/ofac492.294

Ejemplares similares

Ejemplares similares